Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such compounds may either increase or decrease the activity of NR2A-containirig NMDA receptors. The present disclosure also relates to the therapeutic uses of such compounds. Also described are pharmaceutical formulations comprising at least one disclosed compound. Also described herein are methods of treating a disease susceptible to treatment with a disclosed compound in a patient in need thereof by administering to the patient an effective amount of a disclosed compound.Linvention concerne des composés qui modulent négativement et sélectivement des récepteurs NMDA contenant une sous-unité NR2A, des compositions pharmaceutiques comprenant ces composés, et des procédés de traitement dune maladie à laide de ces composés.
